Format

Send to

Choose Destination
Breast Cancer Res Treat. 2020 Apr;180(3):623. doi: 10.1007/s10549-020-05594-6.

Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.

Gonzalez TL1, Hancock M2,3, Sun S4, Gersch CL2,3, Larios JM2,3, David W2,3, Hu J2,3, Hayes DF2,3, Wang S2,3,4,5, Rae JM6,7,8.

Author information

1
Department of Environmental Health Sciences, School of Public Health, University of Michigan, Ann Arbor, MI, 48109, USA.
2
The University of Michigan Rogel Cancer Center, Ann Arbor, USA.
3
Department of Internal Medicine, University of Michigan Medical School, 6310 Cancer Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA.
4
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, USA.
5
Department of Medicinal Chemistry, University of Michigan, Ann Arbor, MI, 48109, USA.
6
The University of Michigan Rogel Cancer Center, Ann Arbor, USA. jimmyrae@med.umich.edu.
7
Department of Internal Medicine, University of Michigan Medical School, 6310 Cancer Center, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109, USA. jimmyrae@med.umich.edu.
8
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, USA. jimmyrae@med.umich.edu.

Abstract

In the original publication of the article, the spelling of the sixth author's given name was incorrect. The corrected author name should read as "Wadie David". The original article has been corrected.

PMID:
32180072
DOI:
10.1007/s10549-020-05594-6

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center